Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer gene hunt: could tumor maps guide better GI cancer treatment?

NCT ID NCT05489250

Knowledge-focused Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at genetic mutations in tumors from 565 people with advanced gastrointestinal cancers, including liver, bile duct, gallbladder, pancreas, esophagus, and stomach cancers. The goal was to see how often these mutations could be targeted by existing drugs and to track whether using genetic information changed treatment decisions. The study was terminated early, so the full impact is unclear.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors choose more targeted treatments for gastrointestinal cancers based on a patient's tumor genetics.
What could go wrong
The study was terminated early, so results may be limited. It was observational, not testing a new treatment directly, so benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

565 people

The number who actually took part.

Started

Oct 2020

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The PLATON Network and its associated pilot study (clinicaltrials.gov:. NCT04484636) enrolls national-wide participants of both sexes and ages over 18 years. All participants are patients diagnosed with hepatocellular cancer (HCC) or intra-/extrahepatic cholangiocellular carcinoma (CCA) or gallbladder carcinoma (GBCA) or pancreatic cancer (PanCa) or esophagogastric cancer (EC/GC). At the time of enrolment life expectancy is at least 6 months and no local curative therapy is available.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed diagnosis of hepatocellular carcinoma or intra- cholangiocarcinoma, extrahepatic cholangiocarcinoma or gallbladder carcinoma or pancreatic ductal adenocarcinoma or esophagogastric adenocarcinoma in the advanced setting (adjuvant or neoadjuvant therapy is allowed if completed 6 months prior to enrolment) and no local curative therapy available * Standard first line therapy is planned, or patient is currently receiving first-line therapy * Available tumor-genomic profile ( ≥50-gene panel assay; approved and assessed by central review), unless central tumor genomic profiling is done within a sub-study * ECOG 0-2 * Life expectancy ≥ 6 months Exclusion Criteria: * Not able to understand all implications of study participation * No written informed consent * Age \< 18 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cholangiocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma esophageal cancer Esophageal Neoplasms extrahepatic bile duct carcinoma gallbladder cancer gallbladder carcinoma gallbladder neoplasm gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma hepatocellular carcinoma intrahepatic cholangiocarcinoma Liver Neoplasms malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm pediatric hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cholangiocarcinoma Gallbladder cancer Hepatocellular cancer Oesophageal cancer Pancreatic cancer Stomach cancer

Contacts and locations

Locations

  • Augusta-Kranken-Anstalt Bochum

    Bochum, Germany

  • Bochum Uni

    Bochum, Germany

  • CaritasKlinikum Saarbrücken

    Saarbrücken, Germany

  • Ev. Kliniken Essen-Mitte, Klinik für Internistische Onkologie

    Essen, 45136, Germany

  • Evangelisches Waldkrankenhaus Spandau

    Berlin, Germany

  • Friedrich-Ebert-Krankenhaus Neumünster

    Neumünster, Schleswig-Holstein, 24534, Germany

  • GEFOS - Gesellschaft für onkologische Studien Dortmund

    Dortmund, Germany

  • HELIOS Klinikum Bad Saarow

    Bad Saarow, Germany

  • Hamburg Onkologische Schwerpunktpraxis Eppendorf

    Hamburg, Germany

  • KHNW Frankfurt

    Frankfurt am Main, Hesse, 60488, Germany

  • Klinik München-Bogenhausen

    München, Germany

  • Klinikum Chemnitz

    Chemnitz, Germany

  • Klinikum Lippe

    Lemgo, Germany

  • Klinikum Ludwigsburg

    Ludwigsburg, Germany

  • Klinikum Rheine, Mathias-Spital Rheine

    Rheine, Germany

  • Klinikum Wolfsburg

    Wolfsburg, Germany

  • Krankenhaus Barmherzige Brüder

    Regensburg, Germany

  • Langen, Gemeinschaftspraxis für Hämatologie und Onkologie

    Langen, Germany

  • MVZ Onkologische Kooperation Harz

    Goslar, Germany

  • MVZ Oskar-Helene-Heim Berlin

    Berlin, Germany

  • Marien Hospital Witten

    Witten, Germany

  • Medius Klinik Osterfildern-Ruit

    Ostfildern, Germany

  • Münster, Gemeinschaftspraxis für Hämatologie und Onkologie

    Münster, Germany

  • Onkologie Bodensee

    Singen, Germany

  • Onkologisches Zentrum Wolfsburg-Helmstedt MVZ GmbH

    Wolfsburg, Germany

  • Onkozentrum Dresden

    Dresden, Germany

  • Ortenau Klinikum Lahr-Ettenheim

    Lahr, Germany

  • St. Anna Hospital Herne

    Herne, Germany

  • Studienzentrum UnterEms

    Leer, Germany

  • Universitätsklinikum Halle (Saale)

    Halle, Germany

  • ÜBAG - MVZ Dr. Vehling-Kaiser GmbH

    Landshut, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.